PhaseV, a leader in AI and machine learning for clinical development, has launched its Trial Optimizer platform on the AWS Marketplace. This milestone provides biopharma sponsors and Contract Research Organizations (CROs) with seamless access to an AI-driven solution designed to enhance clinical trial efficiency, reduce costs, and increase success rates.
PhaseV’s Trial Optimizer launches on AWS Marketplace for biopharma and CROs.
AI/ML platform optimizes phase 1-3 clinical trial designs, reducing costs by up to 50%.
Features include rapid simulations, causal-to-design, and placebo response estimation.
Reduces patient recruitment and trial duration by up to 40%.
Increases trial success probability by over 30%.
Simplifies procurement via AWS Marketplace’s consolidated billing.
The Trial Optimizer platform leverages AI and machine learning to streamline phase 1-3 clinical trial designs, supporting fixed, adaptive, and Bayesian methodologies. It integrates multiple data sources, including sponsor-provided and external data, to evaluate trade-offs such as cost, power, duration, and adaptability. “Bringing Trial Optimizer to AWS Marketplace is a significant milestone for us and, more importantly, for our customers across the globe,” said Raviv Pryluk, PhD, CEO and Co-Founder of PhaseV. The platform’s availability on AWS Marketplace ensures secure, global access to these advanced capabilities.
PhaseV’s Trial Optimizer offers a suite of tools to optimize trial designs:
Rapid Simulation Engine: Runs millions of simulations in minutes, providing visual results to support decision-making and early insights into adaptive interventions like response-adaptive randomization and arm dropping.
Causal-to-Design: Integrates insights from past trials and PhaseV’s data lake to refine inclusion/exclusion criteria and inform development strategies.
Placebo Response Estimation: Models average placebo response rates using relevant study and real-world data.
These features enable teams to explore multiple design scenarios, ensuring alignment with specific goals and constraints.
PhaseV’s platform has delivered significant results, reducing patient recruitment and trial duration by up to 40%, cutting development costs by as much as 50%, and boosting trial success probability by over 30%. By optimizing sample size, alpha allocation, and interim analysis timing, the platform empowers clinical operations, biostatistics, and data science teams to make informed decisions collaboratively.
The Trial Optimizer’s availability on AWS Marketplace simplifies procurement through consolidated billing and predefined agreements, making it easier for organizations to adopt. While additional features like virtual control arms and live trial monitoring dashboards are not yet on AWS Marketplace, the platform’s core capabilities provide immediate value for optimizing clinical development pipelines.
PhaseV’s Trial Optimizer on AWS Marketplace marks a significant step toward revolutionizing clinical trial design. By combining AI-driven insights with AWS’s secure infrastructure, PhaseV enables biopharma and CROs to accelerate therapies to market, reduce costs, and improve outcomes for patients worldwide.
PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions. PhaseV's platform has reduced trial costs by 50%, decreased enrollment size and trial duration by 40%, and increased the probability of trial success by over 30%. To date, the company has delivered results for more than 30 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.